Lilly Pulitzer is serving up a Valentine's Day partnership with Lele Sadoughi, the New York-based accessories brand. Marking their second collaboration, "Lilly Loves Lele" is a six-piece limited ...

The Pulitzer Prize board is asking a judge to hit pause on a defamation case President Donald Trump filed against it until his presidency is over, using Trump’s own legal arguments against him.

Based on Zacks estimates, Eli Lilly’s total sales are now expected to expand 33% in fiscal 2024 to $45.44 billion versus $34.12 billion in 2023. Furthermore, FY25 sales are projected to climb ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...

Eli Lilly and venture capital firm Andreessen Horowitz ... According to STAT, executives from both companies birthed the idea for the fund at a 2023 meet-up, during which they found common ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with its business booming, the company is setting up a similar site 10 hours to the ...

On the one hand, that's still an amazing amount of money. Management notes that it's 45% more than Lilly got in Q4 2023, and that fully 40% of its Q4 money haul, $5.4 billion, will come from sales ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.